Component
Human interleukin-2 receptor alpha / CD25
Species, preparation, dose and limitations are retained on linked claims.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Bromelain reduced surface CD25 on activated human CD4 T cells while soluble CD25 increased, supporting proteolytic shedding.
Experimental context and source evidence
- dose
- Bromelain 25-100 micrograms/mL
- duration
- Up to 8 hours
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Anti-CD3-activated human CD4 T cells
- limitations
- Receptor shedding in activated cells does not establish the net immune effect after oral use.
- nutrient_topic
- Bromelain chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Bromelain
- organism
- Anti-CD3-activated human CD4 T cells
- plain_language
- Bromelain reduced surface CD25 on activated human CD4 T cells while soluble CD25 increased, supporting proteolytic shedding.
- primary_references
- Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro. (2009). https://pubmed.ncbi.nlm.nih.gov/19162239/ DOI: 10.1016/j.intimp.2008.12.012
- route
- In vitro
- tissue
- Surface and soluble CD25
Bromelain: mechanism of action and interactions (2026-09-20) · lines 55–64
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Anti-CD3-activated human CD4 T cells · source_derived_draft · unverified_draft
## bromelain-cd25-cleavage Bromelain reduced surface CD25 on activated human CD4 T cells while soluble CD25 increased, supporting proteolytic shedding. Model/species: Anti-CD3-activated human CD4 T cells Tissue/system: Surface and soluble CD25 Exposure: Bromelain 25-100 micrograms/mL Route: In vitro Duration: Up to 8 hours Limits: Receptor shedding in activated cells does not establish the net immune effect after oral use. Primary reference: Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro. (2009). https://pubmed.ncbi.nlm.nih.gov/19162239/ DOI: 10.1016/j.intimp.2008.12.012 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidenceE64 prevented the bromelain-associated reduction of CD25, showing that the effect required cysteine-protease activity under these conditions.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- dose
- E64 with bromelain
- duration
- Up to 8 hours
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Anti-CD3-activated human CD4 T cells
- limitations
- E64 is an experimental inhibitor; this is a mechanism control, not a treatment comparison.
- nutrient_topic
- Bromelain chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Bromelain
- organism
- Anti-CD3-activated human CD4 T cells
- plain_language
- E64 prevented the bromelain-associated reduction of CD25, showing that the effect required cysteine-protease activity under these conditions.
- primary_references
- Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro. (2009). https://pubmed.ncbi.nlm.nih.gov/19162239/ DOI: 10.1016/j.intimp.2008.12.012
- route
- In vitro co-exposure
- tissue
- Protease-dependence control
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
Bromelain: mechanism of action and interactions (2026-09-20) · lines 66–75
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Anti-CD3-activated human CD4 T cells · source_derived_draft · unverified_draft
## bromelain-e64-dependence E64 prevented the bromelain-associated reduction of CD25, showing that the effect required cysteine-protease activity under these conditions. Model/species: Anti-CD3-activated human CD4 T cells Tissue/system: Protease-dependence control Exposure: E64 with bromelain Route: In vitro co-exposure Duration: Up to 8 hours Limits: E64 is an experimental inhibitor; this is a mechanism control, not a treatment comparison. Primary reference: Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro. (2009). https://pubmed.ncbi.nlm.nih.gov/19162239/ DOI: 10.1016/j.intimp.2008.12.012 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.